| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
eXoZymes Inc. (NASDAQ:EXOZ, formerly Invizyne Technologies))) - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into essential chemicals, medicines, and biofuels - and MDB Capital Holdings (NASDAQ:MDBH) - a premier venture platform for breakthrough technology companies - today announced key leadership changes within the eXoZymes board of directors.
Mo Hayat has transitioned out of his roles as Chairman of the Board and President of eXoZymes, to focus on new MDB Capital ventures. Edgardo Rayo will join the board on behalf of MDB Capital, making it a full circle moment, as he was the MDB Capital team member who discovered the team of scientific co-founders at UCLA and recognized the transformative potential of the science that ultimately evolved into eXoZymes.
Christopher Marlett, CEO of MDB Capital and a current board member of eXoZymes, will assume the role of Chairman to ensure the help and support that MDB Capital will continue to provide eXoZymes.
